GSK shares jump after landmark £1.68bn heartburn drug settlement
The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor confidence in the company.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Shares in drugmaker GSK surged on Thursday after it struck a 2.2 billion US dollar (£1.68 billion) settlement to resolve tens of thousands of lawsuits in the US over its discontinued heartburn drug Zantac.
The company said it had settled with about 80,000 people who brought cases against it in the US – about 93% of all claimants – who alleged that the drug caused cancer.
The sum is seen as a major victory for GSK, after some analysts had estimated the figure would be far higher. JP Morgan’s prediction had been 3.5 billion dollars (£2.68 billion).
GSK has faced a long-running saga around Zantac, which is the brand name for the drug ranitidine.
The product reduces the amount of acid the stomach makes, and was a best-seller in the UK and US in the early 1980s in treating indigestion, heartburn and acid reflux.
It was the first drug to achieve so-called blockbuster status by generating more than a billion dollars in revenue.
But, in 2019, a laboratory in Connecticut reported that it had found “extremely high levels” of NDMA – a substance found in cigarettes and processed foods – when it heated ranitidine.
The drug was discontinued in the UK and the US as a precaution the next year. Other pharmaceutical giants like Pfizer and Sanofi have already reached settlements over similar products.
GSK has since pointed to subsequent research by the US Food and Drug Administration and the European Medicines Agency which has failed to find a causal link between the drug and cancer.
GSK did not accept any liability.
The FTSE 100 drugmaker’s share price was up 6% on Thursday morning as investors cheered the lower-than-expected settlement.
GSK said in a Wednesday evening statement that it will pay for the settlements with existing financial resources, and that it will not bring any change to the company’s “growth agenda or investment plans” for research and development.
Derren Nathan, head of equity research at Hargreaves Lansdown, added that the decision represents a “giant leap towards drawing a line under the long-running legal battle”.
He added that it is a “significantly better outcome than initially expected” and that the settlements “substantially de-risk the investment case for GSK shares which are trading at a hefty discount to the sector”.